Chemours Stock Upgraded to ‘Buy’ by UBS | ORBITAL AFFAIRS

- Advertisement -

Chemours Stock Rises After UBS Upgrade: What Investors Need to Know

Chemours Co. (CC) saw a boost in its shares during intraday trading on Tuesday following an upgrade from UBS analysts. The analysts believe that investors have been overly negative on the chemical company’s stock and see potential for it to outperform in the future.

- Advertisement -

UBS Upgrades Chemours Stock

UBS raised its rating on Chemours from “neutral” to “buy” and increased its price target from $28 to $30. This upgrade comes as the analysts see improving earnings potential for Chemours, particularly in two key areas: colorant titanium dioxide (TiO2) and next-generation refrigerants.

- Advertisement -

Improving TiO2 Earnings

The analysts at UBS believe that Chemours’ TiO2 volumes have been lower than expected due to one-time issues this year. However, they expect these volumes to catch up to competitors over the next year, leading to improved profits in the TiO2 segment. They anticipate sequential improvements in TiO2 earnings throughout the year.

Increasing Demand for Next-Generation Refrigerants

In addition to TiO2, UBS analysts are bullish on Chemours’ next-generation refrigerants, specifically hydrofluoroolefins (HFO). They believe that regulatory efforts to combat global warming will drive demand for lower-emission coolants, benefiting companies like Chemours that offer environmentally friendly refrigerant solutions.

Market Reaction

Following the UBS upgrade, Chemours shares rose approximately 2% to $22.75 as of 2 p.m. ET on Tuesday. Despite this increase, the stock has still experienced a decline of more than 25% in 2024. However, UBS analysts remain optimistic about the company’s future performance based on their assessment of the TiO2 and refrigerants segments.

- Advertisement -

Investor Sentiment

The upgrade from UBS reflects a shift in sentiment towards Chemours stock. By raising their rating to “buy,” the analysts are signaling their confidence in the company’s ability to deliver strong financial results in the coming quarters. Investors who may have been cautious about Chemours in the past may now view the stock more favorably based on UBS’s assessment.

Looking Ahead

As Chemours continues to focus on improving its TiO2 earnings and capitalizing on the growing demand for next-generation refrigerants, investors will be closely watching the company’s performance in these key areas. The UBS upgrade serves as a vote of confidence in Chemours’ strategic direction and growth prospects, potentially attracting new investors to the stock.


The upgrade from UBS has provided a positive catalyst for Chemours stock, leading to a temporary boost in share price. Investors will be monitoring the company’s progress in TiO2 and refrigerants segments to assess whether it can deliver on UBS’s optimistic projections. As always, it is essential for investors to conduct their own research and due diligence before making investment decisions based on analyst recommendations.

For more financial news and updates, visit Investopedia.

News Desk

- Advertisement -

Explore more

Mirzapur Season 3 Review: Excel Entertainment’s Hit Webshow Delivers | ORBITAL...

The third season of Excel Entertainment’s intense crime drama, Mirzapur, has finally arrived, and everyone was eagerly waiting for it after the surprising developments...

Peta Murgatroyd and Maksim Chmerkovskiy Celebrate 7th Wedding Anniversary

Chmerkovskiy raved on Instagram, “Hottest bride I’ve ever seen and easily the best party I’ve ever been a part of,” gushed. Peta Murgatroyd and...

Revolutionizing Leave Management System with Technology | ORBITAL AFFAIRS

If there is a long weekend, employees start to request leave. If all the employees The post How Technology is Secretly Revolutionizing Leave Management System!...

Kymera Therapeutics Skin Diseases Drug Soars with Sanofi Expansion | ORBITAL...

The Partnership Between Kymera Therapeutics and Sanofi Leads to Promising Developments in Skin Disease Treatment Key Takeaways: Kymera Therapeutics shares surged after...

Marisa Abela and Jamie Bogyo Engaged! | ORBITAL AFFAIRS

The actress, who portrayed Amy Winehouse in the recent biopic, said she’s a “weeping mess” following the proposal Another title that can be added...
Kesha's Powerful Response to Body Shaming

Kesha’s Powerful Response to Body Shaming

Singer Kesha has been exposing “body shaming” fans on social media platforms like as X and Instagram. Her comments have become so viral that...

Unlock High-Quality White Hat Backlinks with OutreachKart: Your Trusted Link Building...

In the competition of Search Engine Optimization (SEO), earning high-quality backlinks is very important to improve your site’s authority, visibility, and ranking. By the...
Chipotle Stock Price Retreats from Record Highs: Levels to Watch | ORBITAL AFFAIRS

Chipotle Stock Price Retreats from Record Highs: Levels to Watch |...

Shares Dropped More Than 5% on Monday